Weill Cornell Medical College, New York, NY, USA.
Department of Neurology, NewYork-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.
Epilepsia. 2021 Feb;62(2):337-346. doi: 10.1111/epi.16795. Epub 2020 Dec 20.
Treatment delays for refractory convulsive status epilepticus (RCSE) are associated with worse outcomes. In the United States, treatment for pediatric RCSE is slower than guidelines recommend. To address this gap, the American Academy of Neurology and Child Neurology Society (AAN/CNS) developed a quality measure: the percentage of RCSE patients that receive third-line treatment within 60 minutes. We aimed to develop computable phenotypes for convulsive status epilepticus (CSE) and RCSE to automate calculation of the quality measure.
From an observational cohort of children presenting to the emergency department for seizures or epilepsy, we identified presentations of RCSE and its precursors: CSE and benzodiazepine-resistant status epilepticus (BRSE). These served as a gold standard for computable phenotype development. Using multivariate analyses, we constructed and evaluated statistical models for case identification. We then evaluated adherence to the AAN/CNS RCSE quality measure.
From 664 charts, we identified 56 patients with CSE, 36 with BRSE, and 18 with RCSE. Four predictors were used: International Classification of Diseases (ICD) codes, and receiving first-, second-, or third-line agents shortly after presentation to the emergency department (ED). Combinations of these predictors identified CSE with 84% sensitivity and 81% positive predictive value (PPV), BRSE with 67% sensitivity and 89% PPV, and RCSE with 94% sensitivity and 85% PPV. Median (interquartile range [IQR]) time to treatment for first-line agent was 13 (5-27) minutes for CSE, second-line for BRSE was 24 (9.5-43.5) minutes, and third-line for RCSE was 52 (27-87) minutes. Sixty percent of RCSE patients received a third-line agent within 60 minutes of ED arrival.
RCSE and its precursors can be identified automatically with high fidelity allowing automated calculation of time to treatment and the RCSE quality measure. This has the potential to facilitate quality improvement work and improve care for RCSE.
难治性惊厥性癫痫持续状态(RCSE)的治疗延迟与预后较差相关。在美国,儿科 RCSE 的治疗速度慢于指南建议。为了解决这一差距,美国神经病学学会和儿童神经病学学会(AAN/CNS)制定了一项质量衡量标准:在 60 分钟内接受三线治疗的 RCSE 患者比例。我们旨在开发用于惊厥性癫痫持续状态(CSE)和 RCSE 的可计算表型,以自动计算质量衡量标准。
从急诊就诊的癫痫发作或癫痫患儿的观察队列中,我们确定了 RCSE 及其前驱症状:CSE 和苯二氮䓬类药物抵抗性癫痫持续状态(BRSE)的发作。这些是可计算表型开发的金标准。使用多元分析,我们构建和评估了病例识别的统计模型。然后,我们评估了对 AAN/CNS RCSE 质量衡量标准的遵守情况。
从 664 份图表中,我们确定了 56 例 CSE、36 例 BRSE 和 18 例 RCSE 患者。使用了四个预测因素:国际疾病分类(ICD)代码,以及在急诊就诊后不久接受一线、二线或三线药物。这些预测因素的组合可识别出 CSE 的敏感性为 84%,阳性预测值(PPV)为 81%,BRSE 的敏感性为 67%,PPV 为 89%,RCSE 的敏感性为 94%,PPV 为 85%。一线药物治疗的中位(四分位间距 [IQR])时间为 CSE 为 13(5-27)分钟,BRSE 为 24(9.5-43.5)分钟,RCSE 为 52(27-87)分钟。60%的 RCSE 患者在到达急诊室后 60 分钟内接受了三线药物治疗。
RCSE 及其前驱症状可以高度准确地自动识别,从而能够自动计算治疗时间和 RCSE 质量衡量标准。这有可能促进质量改进工作并改善 RCSE 的护理。